Menu Close
Laura Martin

Dr Martin’s career has focused on filling the translational research void in the development of vaccines for poverty related diseases. Laura joined GSK Vaccines Institute for Global Health (GVGH) in Siena Italy in 2008 when it was owned by Novartis. She currently heads GVGH’s Project Portfolio consisting of vaccines targeting Typhoid and Paratyphoid A fevers, invasive non-typhoidal Salmonella, Shigellosis and Streptococcus A. These vaccines, in preclinical and early clinical development, are based on classical conjugate and novel GMMA technologies as well as traditional recombinant protein approaches. She has guided the vaccines against Typhi and Paratyphi A from preclinical activities through early development and subsequent out licensing and commercialization of a Typhoid Conjugate Vaccine by Biological E. Laura is the principle investigator on grants from the Wellcome Trust (Paratyphoid A and Shigella vaccines) and Bill & Melinda Gates Foundation (Shigella vaccines), to demonstrate proof of concept in humans. Prior to joining GVGH, Laura spent nearly 10 years developing adjuvanted recombinant protein malaria vaccines as a Staff Scientist at the NIH (Rockville, MD, USA) and as a Senior Research Officer at the Queensland Institute of Medical Research (Brisbane, Australia). She obtained her BSc from the University of Wisconsin – Madison and completed her Immunology and Microbiology PhD at the Wayne State University (Detroit, MI, USA). As postdoctoral fellow, she held positions at the Immunology Department at the Mayo Clinic and Foundation (Rochester, MN, USA), Preclinical Research Sandoz-Pharma AG (Basel, Switzerland) and Cellular Molecular Cellular Biology at the University of Queensland (Brisbane, Australia).